Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia
Autore:
Scheepers, FE; de Wied, CCG; Kahn, RS;
Indirizzi:
Univ Utrecht, Med Ctr, Dept Psychiat A00214,POB 85500, NL-3508 GA Utrecht,Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA -3508 GA Utrecht,Netherlands
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 6, volume: 21, anno: 2001,
pagine: 575 - 582
SICI:
0271-0749(200112)21:6<575:TEOOTO>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
D-FENFLURAMINE CHALLENGE; META-CHLOROPHENYLPIPERAZINE; DOUBLE-BLIND; ANTIPSYCHOTIC DRUG; NEUROENDOCRINE RESPONSES; BEHAVIORAL PHARMACOLOGY; SEROTONIN RECEPTORS; CLOZAPINE TREATMENT; PROLACTIN RESPONSE; NEGATIVE SYMPTOMS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
72
Recensione:
Indirizzi per estratti:
Indirizzo: Scheepers, FE Univ Utrecht, Med Ctr, Dept Psychiat A00214,POB 85500, NL-3508 GA Utrecht,Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA ht,Netherlands
Citazione:
F.E. Scheepers et al., "The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia", J CL PSYCH, 21(6), 2001, pp. 575-582

Abstract

In addition to dopamine, serotonin (5-hydroxytryptamine, 5-HT) has been reported to play an important role in schizophrenia. Besides blocking dopamine, atypical antipsychotics also block 5-HT receptors. The clinical efficacyof the atypical antipsychotic clozapine is associated with the 5-HT antagonistic action of the drug and a high serotonergic tone before treatment. The atypical antipsychotic olanzapine has a receptor-binding profile similar to that of clozapine. The present study investigated whether treatment witholanzapine blocks hormone release induced by the 5-HT2c agonist m-chlorophenylpiperazine (m-CPP) and, if so, whether this 5-HT antagonistic effect isrelated to treatment response. Eighteen male schizophrenic patients participated in this study. All patients were challenged with m-CPP (0.5 mg/kg orally) in a double-blind, randomized, placebo-controlled design after a drug-free period of at least 2 weeks. Adrenocorticotropic hormone (ACTH), cortisol, and prolactin plasma levels were measured every 30 minutes up to 210 minutes after challenge. Patients were treated for 6 weeks with 10 mg olanzapine daily in an open design, after which the challenge tests were repeated. Olanzapine significantly blocked m-CPP-induced ACTH, cortisol, and prolactin release, suggesting that it is a potent 5-HT2c antagonist in vivo. This5-HT antagonistic effect of olanzapine was not significantly correlated with treatment response. Also, no significant correlation was found between m-CPP-induced hormone release before treatment and clinical response after treatment with olanzapine. These findings suggest that olanzapine is a potent 5-HT2c antagonist in vivo but that this is up elated to its clinical efficacy in this nonrefractory sample of schizophrenic patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 15:53:33